Open Access
HPV protein/peptide vaccines: from animal models to clinical trials
Steven C Fausch1,Diane M Da Silva1,Gretchen L Eiben1,I Caroline Le Poole1,W Martin Kast1
Cancer Immunology Program, Cardinal Bernardin Cancer Center, Loyola University Chicago, 2160 S. First Avenue, Maywood, IL 60153, USA
DOI: 10.2741/1009 Volume 8 Issue 6, pp.81-91
Published: 01 January 2003
(This article belongs to the Special Issue Papillomaviruses: immunology and vaccines)

Human Papillomaviruses are viruses that infect the epithelial layers of the oral, rectal, vaginal, and cervical mucosa. There is a causal link between the development of cervical cancer and some other cancers and high-risk human papillomavirus infection (1, 2). Currently there is no prophylactic or therapeutic vaccine available against human papillomavirus infection and its associated lesions. In addition, there exists a high degree of species specificity associated with papillomavirus infection precluding human papillomavirus's use in animal models. Therefore, multiple researchers have utilized a variety of homologous animal papillomaviruses and animal model systems for the development of vaccine strategies against papillomaviruses. The goal of their efforts is to identify vaccine strategies that are efficacious in the animal model systems and translate these strategies into human clinical trials against human papillomavirus. The development of such a vaccine would ultimately result in a reduction in the incidence of cervical cancer and some other HPV-linked cancers and may provide therapy for individuals harboring papillomavirus lesions. This review discusses the advances in papillomavirus vaccinology using proteins/peptides, from the work completed in the animal models to the results of the early human clinical trials.

Share and Cite
Steven C Fausch, Diane M Da Silva, Gretchen L Eiben, I Caroline Le Poole, W Martin Kast. HPV protein/peptide vaccines: from animal models to clinical trials. Frontiers in Bioscience-Landmark. 2003. 8(6); 81-91.